medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2014, Number 3

<< Back Next >>

Acta Med Cent 2014; 8 (3)

Immunohistochemical prognostic factors, qualifying constructs and determinant adverse events in overall survival in invasive breast carcinomas

Ruiz JL, Alegret RM, Llombart-Bosh A, Machado PI, Ramos VJ

Language: Spanish
References: 23
Page: 48-56
PDF size: 106.64 Kb.


ABSTRACT

Immunohistochemical prognosis factors or moleculars and qualifying constructs were evaluated for the contribution to overall survival, and adverse events. It was defined a nonrandom sample of 373 women with invasive breast carcinomas operated on a 15-year period (1992-2007). Results: From the evaluated factors the most contributed to overall survival were the p53 with seven patients (three deaths and 57.1% survival to the value 2 +) and 20 cases (five deaths and 75.0% overall survival for the value 3 +); the Bcl2 gene with 47 patients -13 died and 72.3% survival rate for the zero value and 40 cases (five deaths and 87.5% survival rate for the value 1 +); Top Nottingham prognostic index of 5.4 with 91 patients Nottingham greater forecasting 5.4 with 91 patients -38 died, 69.7% overall survival and an average of 9.33 years, stage IV according to the classification TNMp with a female patient -who died, with an average of 1.49 years, followe by the stage IIIC with 31 patients -21 of them dead, 32.3% survival and an average of 4.68 years, the N3 component with 32 patients -22 died, 31.3% overall survival and an average of 4.58 years; the M1component with a female patient -who died, with an average of 1.49 years, local recurrence with 17 patients –nine of them died, 47.1% survival and an average of 9.57 years, and distant metastases with 51 patients - 59 dead, with an overall survival of 13.6% and an average of 5.16 years. Conclusion: p53 positive values and negative of Bcl- 2, the largest group prognosis of 5.4, stages IV and III C, N3 and M1 components, local recurrence and distant metastases were most influenced in overall survival.


REFERENCES

  1. Lester SC. The breast. En: Kumar V, editor. Robbins and Cotran Pathology basis of disease [CD-ROM]. Philadelphia: Elsevier; 2010.

  2. Hurtado Estrada G, Sánchez Forgach E, Miranda Hernández H, Noé Mares Corona J. Factores de pronóstico en cáncer de mama. Gamo. 2004 Abr-Jun;3(2):28-32.

  3. Cruz Chávez FR, Vázquez Márquez Á, Boza Torres PE, Serrat Gómez F, Almirall Chávez ÁM. Supervivencia a los 15 años de pacientes diagnosticadas con cáncer de mama. Ginecol Salud Reprod [Internet]. 2013 [citado 4 May 2013];39(2):[aprox 4 p.]. Disponible en: http://bvs.sld.cu/revistas/gin/vol39_2_13/gin11213.htm

  4. Ruiz Jorge L, Ruiz Méndez AS. Modificaciones al procedimiento anatomopatológico de las mastectomías según Juan Rosai. Acta Méd Centro [Internet]. 2007 [citado 4 May 2013];1(1):[aprox 3 p.]. Disponible en: www.actamedica.sld.cu/r11/modificaciones7.htm

  5. Piñero-Madrona A, Polo-García L, Alonso-Romero JL, Salinas-Ramos J, Canteras-Jordana M, Sola-Pérez J, et al. Características inmunohistoquímicas del cáncer de mama: ¿hacia una nueva clasificación? Cir Esp. 2008;84(3):138-45.

  6. Hosaka N, Ryu T, Cui W, Li Q, Nishida A, Miyake T, et al. Relationship of p53, Bcl-2, Ki- 67 index and E-cadherin expression in early invasive breast cancers with comedonecrosis as an accelerated apoptosis. J Clin Pathol. 2006;59:692–8. doi: 10.1136/jcp.2005.030296.

  7. Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol. 2008 Jun;61(6):689-96. Epub 2007 Nov 23.

  8. Talley LI, Chhieng DC, Bell WC, Grizzle WE, Frost AR. Immunohistochemical detection of EGFR, p185erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and postmenopausal women. Biotechnic Histochemistry. 2008 Feb;83(1):5-14. doi: 10.1080/10520290701822436.

  9. Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci. 2008;99:324– 32.

  10. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index. Clin Cancer Res. 2006 Apr 15;12:2468-75.

  11. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010 Aug 24;103(5):668–75. Published online 2010 July 27. doi:10.1038/sj.bjc.6605736 PMCID: PMC2938244

  12. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 1993;25(3):283.

  13. Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer. 2012 Oct 1;131(7):e1109-19. doi: 10.1002/ijc.27539.

  14. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V. Tumours of the breast. En: Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of the breast and female genital organs. Lyon: OMS; 2003. p. 10-59.

  15. Davion SM, Siziopikou KP, Sullivan ME. Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers. Histopathology. 2012 Jul 2;61(4):660-6. doi: 10.1111/j.1365-2559.2012.04253.x.

  16. Luo MH, Huang YH, Ni YB, Tsang JY, Chan SK, Shao MM. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Hum Pathol. 2013 Jul;44(7):1241-50. doi: 10.1016/j.humpath.2012.10.009.

  17. Díaz-Rosales JD. Ganglio centinela y cáncer de mama. Electrón J Biomed. 2009;1:40-5.

  18. Grupo editorial del programa integral para el control del cáncer. Cáncer de mama: Guía de práctica clínica en diagnóstico y tratamiento. México: CENETEC; 2013. p. 13.

  19. Risk factors for loco-regional breast cancer recurrence among breast. J Clin Oncol. 2003 Apr 1;21(7):1205-13.

  20. Marret H, Perrotin F, Bougnoux P, Giraudeau y colbs. Histologic multifocality is predictive of skin recurrences after conserving treatment of stage I and II breast cancers. Breast Cancer Res Treat. 2001 Jul;68(1):1-8.

  21. Le MG, Arriagada R, Spielmann M, Guinebretiere JM y colbs. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer. 2002 Jun 1;94(11):2813-20.

  22. Arriagada R, Le MG, Contesso G, Guinebretiere JM y colbs. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002 Sep;13(9):1404-13.

  23. Chang J, Clark GM, Allred DC, Mohsin S y colbs. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003 Feb 1;97(3):545-53.




2020     |     www.medigraphic.com